Alterity Therapeutics Limited

1.24-0.0400-3.13%Vol 30.14K1Y Perf 104.68%
Apr 19th, 2021 10:11 DELAYED
BID1.23 ASK1.25
Open1.25 Previous Close1.28
Pre-Market- After-Market-
 - -%  - -
Target Price
- 
Analyst Rating
— 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★★     65.71
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap28.03M 
Earnings Rating
Price Range Ratio 52W %
15.00 
Earnings Date
2nd Oct 2020

Today's Price Range

1.231.29

52W Range

0.55005.15

5 Year PE Ratio Range

-5.00-1.90

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-7.91%
1 Month
-20.50%
3 Months
-20.00%
6 Months
-30.43%
1 Year
104.68%
3 Years
-31.91%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ATHE1.24-0.0400-3.13
AAPL134.490.33000.25
GOOG2 290.42-7.3400-0.32
MSFT259.22-1.5200-0.58
XOM56.41-0.2500-0.44
WFC44.140.30000.68
JNJ162.410.17000.10
FB302.79-3.3900-1.11
GE13.26-0.1300-0.97
JPM152.61-0.6900-0.45
Financial StrengthValueIndustryS&P 500US Markets
12.20
12.30
0.00
0.00
-
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
-
202.87K
201.67K
-7 591.60
-
RevenueValueIndustryS&P 500US Markets
-5 781.00
0.00
-17.72
-13.83
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume30.14K
Shares Outstanding22.60M
Trades Count119
Dollar Volume568.45K
Avg. Volume619.76K
Avg. Weekly Volume163.98K
Avg. Monthly Volume146.60K
Avg. Quarterly Volume648.44K

Alterity Therapeutics Limited (NASDAQ: ATHE) stock closed at 1.28 per share at the end of the most recent trading day (a 0.79% change compared to the prior day closing price) with a volume of 191.48K shares and market capitalization of 28.03M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 12 people. Alterity Therapeutics Limited CEO is Geoffrey Paul Kempler.

The one-year performance of Alterity Therapeutics Limited stock is 104.68%, while year-to-date (YTD) performance is -4.48%. ATHE stock has a five-year performance of %. Its 52-week range is between 0.55 and 5.15, which gives ATHE stock a 52-week price range ratio of 15.00%

Alterity Therapeutics Limited currently has a PE ratio of -2.20, a price-to-book (PB) ratio of 1.87, a price-to-sale (PS) ratio of -7 690.54, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -63.12%, a ROC of -71.91% and a ROE of -71.91%. The company’s profit margin is -%, its EBITDA margin is 201 674.00%, and its revenue ttm is $-5 781.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Alterity Therapeutics Limited, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Alterity Therapeutics Limited’s next earnings report date is -.

The consensus rating of Wall Street analysts for Alterity Therapeutics Limited is (0), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Alterity Therapeutics Limited stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Alterity Therapeutics Limited has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Alterity Therapeutics Limited has a Sell technical analysis rating based on Technical Indicators (ADX : 28.69, ATR14 : 0.16, CCI20 : -133.67, Chaikin Money Flow : -0.19, MACD : -0.14, Money Flow Index : 25.89, ROC : -9.86, RSI : 43.21, STOCH (14,3) : 20.63, STOCH RSI : 0.71, UO : 48.09, Williams %R : -79.37), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Alterity Therapeutics Limited in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
1 (100.00 %)
Moderate Buy
0
0
0 (0.00 %)
Hold
0
0
0 (0.00 %)
Moderate Sell
0
0
0 (0.00 %)
Strong Sell
0
0
0 (0.00 %)
Summary Rating--Strong Buy
1.00

Alterity Therapeutics Limited

Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaboration with Takeda for the treatment of Parkinson's disease gastrointestinal neuropathology. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434).

CEO: Geoffrey Paul Kempler

Telephone: +61 393494906

Address: 460 Bourke Street, Melbourne 3000, VIC, AU

Number of employees: 12

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

71%29%

Bearish Bullish

58%42%

Bearish Bullish

61%39%

News

Stocktwits